Axonics, Medtronic
Axonics defeats Medtronic lawsuit in spine-stimulation patent trial
Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's patent rights in nerve-stimulation technology.
Jury rules for Axonics in Medtronic’s long-running neuromodulation patent lawsuit
A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run afoul of three patents held by the company’s main rival, Medt | The case is one of several intellectual property disputes between the medtech giant and Axonics—which is currently waiting to become a subsidiary of Boston Scientific.
Axonics did not infringe Medtronic’s patents, jury rules
The Court for the Central District of California has sided with Axonics finding the company did not breach Medtronic’s patents with its r-SNM devices.
Medtronic loses $150M spine patent suit
California-based medical device company Axonics has won a patent infringement trial against Medtronic, according to a Sept. 19 report from Global Data. Medtronic alleged that the company copied three elements of its sacral neuromodulation technology and sought $150 million from the device manufacturer.
Jury says Axonics didn’t infringe on Medtronic patents
Axonics (Nasdaq:AXNX) announced today that a jury unanimously ruled in its favor in a patent spat with (NYSE: MDT).
Axonics gains after win in trial in patent dispute with Medtronic
Axonics Inc. (NASDAQ:AXNX) rose 1.5% in after hours trading after a jury voted in is favor in a patent dispute with Medtronic (MDT). Medtronic (MDT) was seeking $150 million in a patent dispute with Axonics (AXNX),
Medtronic’s Aurora EV-ICD to challenge Boston Scientific’s S-ICD market leadership
"Medtronic’s Aurora EV-ICD to challenge Boston Scientific’s S-ICD market leadership" was originally created and published by ...
Minnesota man among first to receive new Parkinson's device
Medtronic's latest Deep Brain Stimulation device allows Bruce Lunde to control his tremors remotely, with a cell phone, and ...
STAT5d
Most cardiovascular devices with serious safety recalls aren’t tested in patients
The analysis comes as regulators investigate how the FDA authorizes medical devices and handles safety recalls.
FierceBiotech3d
Awaiting FDA review, Medtronic details study of adaptive neurostimulation in Parkinson’s disease
ADAPT-PD is a randomized crossover study that has enrolled 68 patients implanted with Medtronic’s Percept PC ...
MassDevice1d
Medtronic has a new VP, GM for TAVR, Congenital Heart
Medtronic (NYSE: MDT) has named Jorie Soskin as its new VP and GM of its TAVR and Congenital Heart businesses.
Medtronic: An Undervalued Stock With Durable Competitive Advantages
Medtronic, a global developer and manufacturer of medical devices for chronic diseases, is now a $111 billion (by market cap) ...